Navigation Links
Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/7/2009

harma.com/" target="_new">http://www.optimerpharma.com.

Forward-looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the development of fidaxomicin and prulifloxacin, the timing of clinical trials and anticipated results, and plans related to regulatory filings, including a potential MAA for fidaxomicin. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the timing, progress and likelihood of success of its product research and development programs, the timing and status of its preclinical and clinical development of potential drugs, uncertainty regarding regulatory requirements for approval, the timing of regulatory submissions and the uncertainty regarding whether such submissions will be accepted or approved, and other risks detailed in Optimer's filings with the Securities and Exchange Commission.

                        Optimer Pharmaceuticals, Inc.
                    Consolidated Statements of Operations
                                 (unaudited)

                                                  Three Months Ended March 31,
                                                  ---------------------------
                                                         2009         2008
                                                         ----        
'/>"/>
SOURCE  Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 

Related biology technology :

1. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
3. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
4. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
5. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
6. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
7. Idenix Pharmaceuticals Reports First Quarter Financial Results
8. Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
9. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
10. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
11. Vanda Pharmaceuticals Reports First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... rejection occurs when the transplant recipient,s immune system identifies ... It was previously thought that T cells, the immune ... molecules known as chemokines in order to migrate to ... Journal of Clinical Investigation , Fadi Lakkis and colleagues ... that chemokine stimulation of T cells is not required ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 The new ... Photonics21 at the association’s recent annual meeting drew ... EC Vice-President Neelie Kroes, who called the action “a ... and a stimulant to European innovation.” , The Board ... of the new Photonics PPP at its 29 April ...
(Date:5/17/2013)... PALO ALTO, Calif. , May 17, 2013 ... that it has achieved 50% enrollment of the ... trial to evaluate the safety and preliminary efficacy ... Progenitor Cells) therapy for Knee Osteoarthritis (KOA). To ... Effect (SAE) reported. The Phase I ...
(Date:5/17/2013)...  Insero Health, Inc., a company developing natural compounds ... neurological disorders, is today reporting top-line results from a ... patients with drug-resistant epilepsy.  The data are being presented ... meeting by Dr. Steven Schachter , ... Advisory Board.  In this study, INS001 appeared safe and ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
... Website Tackles Water Safety, Environmental Concerns With Test Kits, Water ... Filters and ... That is the,question. At least it is in the minds of ... aren,t sure if their tap water is,safe. Discover Testing has assembled ...
... REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, ... ), a leader in,the development of microRNA-based ... Scientist Prof. Zvi Bentwich will present AACR,s,upcoming ... Bentwich,s presentation will focus on Rosetta Genomics,unique ...
... Sept. 12 Elekta is pleased to,announce the ... Volumetric Intensity Modulated Arc Therapy (VMAT)*. The complete,offering ... the Elekta booth at,this year,s European Society of ... 2007. Performing VMAT with Elekta,enables helical- like conformality ...
Cached Biology Technology:Discover Testing Settles the Drinking Water Debate: Tap vs. Bottled 2Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference 2Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO 2Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO 3
(Date:5/18/2013)... 2013) The AGA Research Foundation is honored to ... Award in Digestive Cancer, which will support Andrew D. ... the University of Pennsylvania, Philadelphia, as he furthers his ... regeneration and cancer progression. , "The AGA Research Foundation ... two distinguished clinicians and AGA Legacy Society members," said ...
(Date:5/17/2013)... By day, insects provide the white noise of the South, ... typical year, the Southern air hangs heavy from the humidity ... to more than 140 species of frogs, toads and salamanders, ... If the ponds and swamps are the auditorium for their ... Research and Monitoring Initiative, or ARMI, have front-row seats. ...
(Date:5/17/2013)... project (Intelligent Cargo in Efficient and Sustainable Global Logistics ... an improvement in the efficiency of intermodal loading systems ... making. It comprises 29 European organisations with experience in ... has a budget totalling 17,000,000 and a duration of ... to specify and develop the semantic components and ontologies ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4New logistics services that will cut energy consumption and CO2 emissions 2
... ORLANDO, Fla., June 30, 2011 Biomechanical testing of ... HULC™ exoskeleton is now underway at the U.S. Army ... Mass.  The testing is expected to help shape future ... (Photo:   http://photos.prnewswire.com/prnh/20110630/FL28804 ) ...
... progenitor cells may not come with a clean genetic slate ... FASEB Journal ( http://www.fasebj.org ) shows that adult stem ... change once a cell differentiates. This is important because epigenetic ... cell,s DNA, but rather, how that DNA functions. Epigenetic changes ...
... California and other premium winegrowing regions of the United ... new study led by Stanford University climate scientists. ... Research Letters , the scientists ,report that by 2040, ... grapes in high-value areas of northern California could shrink ...
Cached Biology News:Lockheed Martin's HULC™ Robotic Exoskeleton Enters Biomechanical Testing at U.S. Army Natick Soldier Systems Center 2Adult stem cells carry their own baggage: Epigenetics guides stem cell fate 2Global warming could alter the US premium wine industry in 30 years, says Stanford study 2Global warming could alter the US premium wine industry in 30 years, says Stanford study 3Global warming could alter the US premium wine industry in 30 years, says Stanford study 4
... NGGC3' 3'CGGN NNNNCCG5' Inactivation Conditions: Heat inactivation ... treatment followed by ethanol precipitation. Storage Conditions: ... EDTA, 1.0mM DTT, 0.01% BSA, 50% glycerol. ... Store at -20C. Unit Definition: One unit ...
...
Anti-Tissue Trans-glutaminase (IgA) EIA Sample Size: 10 l...
... Lysozyme Assay Kit (E-22013) provides,researchers with ... of lysozyme,activity in solution. This fluorescence-based ... 20 U/mL (Figure 1). The assay,measures ... which are labeled to such a ...
Biology Products: